[Other] Baseline tumor size as an independent prognostic factor for overall survival in patients with metastatic melanoma treated with the anti-PD-1 monoclonal antibody MK-3475.

nitin.kumar668 Post time Half hour(s) ago | Show all posts |Read mode

This post will be closed automatically in 2026-09-28 15:20

Reward20points

journal：Journal of Clinical Oncology

Authors：Richard Wayne Joseph; Jeroen Elassaiss-Schaap; Jedd D. Wolchok; Anthony M. Joshua; Antoni Ribas; F. Stephen Hodi; Omid Hamid; Caroline Robert; Adil Daud; Wen-Jen Hwu; Richard Kefford; Peter Hersey; Jeffrey S. Weber; Amita Patnaik; Dinesh Prasad De Alwis; Andrea Marie Perrone; Soonmo Peter Kang; Scot Ebbinghaus; Keaven M. Anderson; Tara C. Gangadhar

Published date：2014-5-20

DOI：10.1200/jco.2014.32.15_suppl.3015

PDF link：http://ascopubs.org/doi/pdfdirec ... 14.32.15_suppl.3015

Article link：https://doi.org/10.1200/jco.2014.32.15_suppl.3015

Article Source：American Society of Clinical Oncology (ASCO)。

Remark：

You can support us by donating, we would be very grateful.

Reply

Use magic Donate Report

All Reply0 Show all posts

Reply

nitin.kumar668 Lv.2

Junior Member

post
reply
points
0

[Other] Baseline tumor size as an independent prognostic factor for overall survival in patients with metastatic melanoma treated with the anti-PD-1 monoclonal antibody MK-3475.

Reply

Same Category

Latest Reply

Announcement

Daily Top Contributors

[Other] Baseline tumor size as an independent prognostic factor for overall survival in patients with metastatic melanoma treated with the anti-PD-1 monoclonal antibody MK-3475. Copy

Reply

Same Category

Latest Reply

Announcement

Daily Top Contributors

[Other] Baseline tumor size as an independent prognostic factor for overall survival in patients with metastatic melanoma treated with the anti-PD-1 monoclonal antibody MK-3475.